个人简介：

Wenru Song, MD, PhD President & Head of R&D, Co-founder Dr. Wenru Song is the co-founder, President and Head of R&D of Kira Pharmaceuticals, a new biotech startup based on cutting-edge immunological sciences. Dr. Song was most recently as the global VP and global clinical leader of Immuno-Oncology development at AstraZeneca Global Medicines. Previously, Dr. Song was the Head of Regional Oncology Development in Asia-Pacific at Millennium/Takeda Oncology, and global clinical lead at Pfizer Immuno-oncology. Prior to joining the pharma-industry, he was an associate investigator at Baylor Institute of Immunology Research and an attending oncologist physician at Baylor Sammons Cancer Center. He studied Medicine in Shandong University and PhD in Immunology at Texas A&M University, with internal medicine training at Montefiore Medical Center/Albert Einstein College of Medicine and medical oncology fellowship at Stanford University.

公司简介：

OUR MISSION Advancing transformative therapies for patients with complement-mediated diseases Named after a patient with complement 3 glomerulopathy (C3G), Kira Pharmaceuticals is driven by the opportunity for impact with the mission to advance transformative therapies for patients around the world with complement-mediated diseases. Kira Pharmaceuticals is a clinical-stage biotechnology company pioneering a world free from complement disease. Enabled by its LOGIC platform, the company has developed a robust pipeline of nine (9) novel complement assets since its inception in 2017, focused on validated targets across the complement cascade. With an experienced team of complement biology experts, drug developers, protein engineers and leaders from across the pharma and biotech industry, Kira Pharmaceuticals is uniquely positioned to tackle some of the most complex and toughest challenges in the complement space and to deliver first-in-class and best-in-class therapies to transform the lives of patients.